DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

The key reason to buy the Dexcom Stelo is not just price, although this plays a big part. The Stelo offers excellent information designed to help you learn more about diabetes, blood sugar ...

With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform. Stelo, the first over-the-counter glucose biosensor ...

In March 2024, the Food and Drug Administration cleared Dexcom’s Stelo as the first over-the ... Additionally, eating foods in a specific order—like eating the lettuce and tomato first ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans ... on the stock with a $100.00 price target. TipRanks tracks over ...

The flagship G7 and DexCom ONE+ platforms continued to drive adoption internationally, with launches in key regions such as France, Australia and Japan bolstering growth. Early success with the newly ...